Papillary thyroid cancer medical therapy

Treatment options for papillary thyroid cancer differes according to the stage and invasion of the tumor and include surgery, external beam radiation therapy ( EBRT), Thyroid suppression therapy, and targeted therapy.

• Treatment options for papillary thyroid cancer include:^[1]

• Pharmacologic medical therapies for papillary thyroid cancer include thyroid-suppression therapy, and/or targeted therapy.

• TSH suppression with thyroxine is effective in many lesions that are not sensitive to 131I.

• This type of treatment is done using:^[2][3]
  • Sorafenib, an Sorafenib is an orally active, multityrosine kinase inhibitor.
  • Lenvatinib, an orally active, multitargeted tyrosine kinase inhibitor.^[4]
    • Adult
      • Preferred regimen: Lenvatinib 24 mg PO daily until disease progression or unacceptable toxicity.
      • Alternative regimen: Sorefenib 400 mg PO q12h until disease progression or unacceptable toxicity.
      • Alternative regimen: Larotrectinib 100 mg PO q12h until disease progression or unacceptable toxicity.
      • Alternative regimen: Entrectinib 600 mg PO daily until disease progression or unacceptable toxicity.

Template:WikiDoc Sources